IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients

Table 2

Clinical features of the patients with mutations in IDH1/IDH2 and TP53 genes.

Clinical characteristics	N (𝑛=106)	IDH1/IDH2 mutated (𝑛=14)	TP53 mutated (𝑛=37)
Gender
Male	53	8 (15.1%)	20 (37.7%)
Female	53	6 (11.3%)	17 (32.1%)
Age
<56 years old	51	12 (23.5%)	22 (43.1%)
≥56 years old	55	2 (0.36%)	15 (27.3%)
Karnofsky Scale^a
KPS ≤70	56	3 (0.5%)	15 (26.8%)
KPS >70	45	10 (22.2%)	21 (46.6%)
Resection^a
Subtotal or partial	54	10 (18.5%)	21 (38.8%)
Total	50	4 (0.8%)	16 (32%)
Glioblastoma type
Primary	93	10 (10.7%)	29 (31.2%)
Secondary	13	4 (30.7%)	8 (61.5%)
Overall survival^a (months)
Median	7.7	30.9	9.1

aMissing data for several patients.
N: number of patients.